Literature DB >> 8783012

Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry.

A Ducret1, C F Bruun, E J Bures, G Marhaug, G Husby, R Aebersold.   

Abstract

A detailed structural analysis of the serum amyloid A proteins (SAA) of an individual with highly active, chronic rheumatoid arthritis is reported. SAA isoforms were separated by high-resolution two dimensional (2-D) gel electrophoresis. Peptide mapping by reverse-phase chromatography/electrospray ionization tandem mass spectrometry was applied to correlate the protein(s) contained in each spot with their respective coding gene and to study the post-translational processing and modification events which might result in differential electrophoretic mobility. Nine protein spots were analyzed. The six major spots corresponded to the Arg and des-Arg forms of SAA1 alpha and SAA2 alpha, respectively, and to the glycosylated and nonglycosylated form of constitutive serum amyloid A protein (C-SAA). Two minor spots were identified as SAA1 alpha isoforms containing post-translational modifications. We suggest that these variants contained a gamma-N, N'-dimethylasparagine residue at position 83 and that one of them was additionally oxidized at Trp53 and Trp85. The ninth spot was shown to contain a mixture of SAA1 alpha and SAA2 alpha. To our knowledge, this is the first report in which analysis of peptides has been used to verify the presence of C-SAA in acute-phase serum. Furthermore, the data illustrate that extensive post-translational processing results in a structurally diverse class of acute-phase SAA proteins, which are derived from a small number of genes. Finally, the fast and conclusive technology used in this study promises to be generally useful for the comprehensive investigation of proteins at the level of the primary structure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8783012     DOI: 10.1002/elps.1150170508

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  13 in total

Review 1.  Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms.

Authors:  Olgica Trenchevska; Randall W Nelson; Dobrin Nedelkov
Journal:  Bioanalysis       Date:  2016-07-11       Impact factor: 2.681

2.  Serum amyloid A levels are associated with polymorphic variants in the serum amyloid A 1 and 2 genes.

Authors:  Kayleigh Griffiths; Alexander P Maxwell; Rachel V McCarter; Patrick Nicol; Ruth E Hogg; Mark Harbinson; Gareth J McKay
Journal:  Ir J Med Sci       Date:  2019-03-09       Impact factor: 1.568

3.  Development of quantitative mass spectrometric immunoassay for serum amyloid A.

Authors:  Olgica Trenchevska; Hussein N Yassine; Chad R Borges; Randall W Nelson; Dobrin Nedelkov
Journal:  Biomarkers       Date:  2016-07-22       Impact factor: 2.658

4.  Mouse serum amyloid A (SAA) proteins isolated by two-dimensional electrophoresis: characterization of isotypes and the effect of separate and combined administrations of cytokines, dexamethasone and lipopolysaccharide (LPS) on serum levels and isotype distribution.

Authors:  C Foyn Bruun; K Sletten; G Marhaug
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

5.  High throughput protein characterization by automated reverse-phase chromatography/electrospray tandem mass spectrometry.

Authors:  A Ducret; I Van Oostveen; J K Eng; J R Yates; R Aebersold
Journal:  Protein Sci       Date:  1998-03       Impact factor: 6.725

6.  Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.

Authors:  S L Wood; M Rogers; D A Cairns; A Paul; D Thompson; N S Vasudev; P J Selby; R E Banks
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

7.  High-density lipoprotein proteome dynamics in human endotoxemia.

Authors:  Johannes Hm Levels; Pierre Geurts; Helen Karlsson; Raphaël Marée; Stefan Ljunggren; Louise Fornander; Louis Wehenkel; Mats Lindahl; Erik Sg Stroes; Jan A Kuivenhoven; Joost Cm Meijers
Journal:  Proteome Sci       Date:  2011-06-28       Impact factor: 2.480

8.  Serum amyloid a truncations in type 2 diabetes mellitus.

Authors:  Hussein N Yassine; Olgica Trenchevska; Huijuan He; Chad R Borges; Dobrin Nedelkov; Wendy Mack; Naoko Kono; Juraj Koska; Peter D Reaven; Randall W Nelson
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

Review 9.  Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.

Authors:  Olgica Trenchevska; Randall W Nelson; Dobrin Nedelkov
Journal:  Proteomes       Date:  2016-03-17

10.  Investigation of the solubility and the potentials for purification of serum amyloid A (SAA) from equine acute phase serum--a pilot study.

Authors:  Michelle B Christensen; Jens Christian Sørensen; Stine Jacobsen; Mads Kjelgaard-Hansen
Journal:  BMC Res Notes       Date:  2013-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.